John Hunter

John Hunter has over 35 years of work experience in the biotechnology and pharmaceutical industry. John is currently working as the Chief Scientific Officer at FibroGen, Inc. Prior to that, they served as the Chief Executive and Scientific Officer at Keyhole Therapeutics, Inc. where they led the development of immune modulating therapeutics for the treatment of cancer and autoimmune diseases.

Before joining Keyhole Therapeutics, John worked at Compugen as the Chief Scientific Officer and US Site Head. John was responsible for setting the strategic direction and managing a 65-person R&D team. John also led drug development efforts resulting in collaborations and first-in-class clinical immune checkpoint inhibitors.

Prior to Compugen, John held various roles at XOMA, including Senior Director and Principal Scientist. John managed a group responsible for antibody discovery and served in key strategic roles relating to XOMA's antibody pipeline. John also worked as a Sr Scientist at Xenogen Corporation and Millennium Pharmaceuticals.

John's work experience also includes being a Lab Tech at the Whitehead Institute and Rosenstiel Center early in their career. Throughout their career, John has demonstrated expertise in scientific leadership, drug development, and strategic management in the biotech industry.

John Hunter received their Bachelor of Arts degree in Biology from Hartwick College, where they studied from 1981 to 1985. Later on, they pursued their PhD in Immunology at the University of California, San Francisco, completing their studies from 1991 to 1996.